<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Pharmaceutical Sciences</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/31190889-A152-4789-B093-2ACBCBDE7467"><gtr:id>31190889-A152-4789-B093-2ACBCBDE7467</gtr:id><gtr:firstName>Maya</gtr:firstName><gtr:surname>Thanou</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FF003188%2F2"><gtr:id>D8750693-1991-4E50-95EF-D937DD3DFA63</gtr:id><gtr:title>Enzyme-Triggerable Stealth Release (ETSR) of targeted nanoparticles for cancer gene therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/F003188/2</gtr:grantReference><gtr:abstractText>Targeted drug delivery to disease tissues like tumours is the ultimate therapeutic strategy. If drugs can accumulate in tumour tissue, then unwanted side effects including cellular toxicity can be avoided and therapeutic effects may be improved since both dose and efficacy can increase. In this project our main aim is to harness the potential of nanomedicine by preparing self-assembly, synthetic nanoparticles that carry drugs inside but have and a polymer coating on the outside. However, while the polymer coating is excellent in helping to improve blood-circulation times, local release of encapsulated drugs in or near tumour target cells is heavily impaired. This problem should be soluble by ensuring that the polymer can be released at the required time inside the tumour itself bringing cell death exclusively to tumour cells. Our specific approach is to introduce polymers with peptide sequences that are also substrates for tumour specific enzymes. When such peptide modified nanoparticles reach tumours, those enzymes present should then strip-off the polymer coating revealing core nanoparticles that can easily enter cells and deliver encapsulated drug(s) to local tumour cells. We will construct these nanoparticles by preparing all necessary building blocks chemically and assemble these in such way that peptide sequences will be readily available for the tumour specific enzyme(s). Nucleic acids will used as the first drugs since these can be very specific and are arguably safer than the anticancer cytotoxic agents.</gtr:abstractText><gtr:fund><gtr:end>2011-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>79804</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings have been used to continue research in the area of anticancer agents. A number of pharmaceutical companies have shown interest in the use of this technology</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>FC6BBC6E-E4AC-4FD6-BCED-F251CD322648</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>546228d8387353.37147966</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have developed a liposomal nanoparticle that takes advantage of the enzymes present in the tumour to &amp;quot;transform&amp;quot; into a more cell invasive anticancer drug carrier.
We have done experiments in cells and in vivo and both studies agree that MMP-2 (cancer enzyme) can cleave off the stealth protection of the nanoparticles and improve their uptake by cancer cells</gtr:description><gtr:exploitationPathways>In the design of anticancer therapies</gtr:exploitationPathways><gtr:id>95596F09-3666-4ADD-99B5-5724FC13F714</gtr:id><gtr:outcomeId>5462285c6a1331.32363334</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3CB1EB50-7A1A-4D9E-94C1-36F2F81631EC</gtr:id><gtr:title>Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles.</gtr:title><gtr:parentPublicationTitle>Journal of drug targeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/737ffe0e530a693d7c0da01892f1528d"><gtr:id>737ffe0e530a693d7c0da01892f1528d</gtr:id><gtr:otherNames>Wang M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1026-7158</gtr:issn><gtr:outcomeId>56d7f95656a648.33080430</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA29C8E-C4A0-450C-B4B7-53411356742F</gtr:id><gtr:title>pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ade9479bb633e247d863554bb61df3"><gtr:id>91ade9479bb633e247d863554bb61df3</gtr:id><gtr:otherNames>Kolli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>56d7f7f85df392.08871390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CF0363E-9631-4A30-BB93-B2E0B644D6A4</gtr:id><gtr:title>Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA.</gtr:title><gtr:parentPublicationTitle>Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6003593023f8e2e7bcab079098e33009"><gtr:id>6003593023f8e2e7bcab079098e33009</gtr:id><gtr:otherNames>Yingyuad P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1747-0854</gtr:issn><gtr:outcomeId>56d7f956296426.80308022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>514EFC0F-B838-4E4E-AAEB-3666C3566209</gtr:id><gtr:title>Improved Synthesis of Linear Poly(ethylenimine) via Low-Temperature Polymerization of 2-Isopropyl-2-oxazoline in Chlorobenzene</gtr:title><gtr:parentPublicationTitle>Macromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4a2ccf19af2ff83b6412508c2e4f18e"><gtr:id>b4a2ccf19af2ff83b6412508c2e4f18e</gtr:id><gtr:otherNames>Monnery B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0024-9297</gtr:issn><gtr:outcomeId>56d7f7f7d00e83.73000777</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/F003188/2</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>C8D1082D-41F7-4B55-B2D9-90B2D9915DA8</gtr:id><gtr:grantRef>EP/F003188/1</gtr:grantRef><gtr:amount>387512.78</gtr:amount><gtr:start>2007-11-12</gtr:start><gtr:end>2010-04-30</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>D8750693-1991-4E50-95EF-D937DD3DFA63</gtr:id><gtr:grantRef>EP/F003188/2</gtr:grantRef><gtr:amount>79804.3</gtr:amount><gtr:start>2010-09-01</gtr:start><gtr:end>2011-07-31</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E48C802F-8897-4353-910A-09D09331BB82</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Medical science &amp; disease</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>